• Histologic or radiographic diagnosis of hepatocellular carcinoma

• At least one lesion amenable to TACE treatment

• Child-Pugh A-B7 (B7 based on Albumin allowed)

• Not a candidate for resection or transplantation

• Age ≥ 18 years.

• Performance status: ECOG performance status ≤2

• Must have at least one measurable lesion (either untreated or progressed after previous locoregional treatment)

• Adequate organ and marrow function as defined below:

∙ Leukocytes ≥ 2,000/mcL

‣ absolute neutrophil count ≥ 1000/mcL

‣ platelets ≥ 60,000/mcl

‣ total bilirubin within normal institutional limits

‣ AST(SGOT)/ALT(SPGT) ≤ 3 X institutional upper limit of normal or ≤ 5 X if liver metastases are present

‣ creatinine \<1.5ULN

‣ hemoglobin ≥ 8 g/dL

‣ Serum albumin ≥ 2.8 g/dL

‣ Urine protein/creatinine ration (UPCR) ≤ 1 mg/mg

• The effects of cabozantinib on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 4 months following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

• Based on its mechanism of action, ipilimumab can cause fetal harm when administered to a pregnant woman. Females of reproductive potential must use effective contraception during treatment with ipilimumab and for 3 months following the last dose of ipilimumab.

• Based on its mechanism of action, nivolumab can cause fetal harm when administered to a pregnant woman. Females of reproductive potential must use effective contraception during treatment with nivolumab and for 5 months following the last dose of nivolumab.

• 1\. A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

⁃ Has not undergone a hysterectomy or bilateral oophorectomy; or

⁃ Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).

∙ Life expectancy of greater than 3 months

‣ Ability to swallow tablets

‣ Ability to understand and the willingness to sign a written informed consent.